American biotech giant shaping biopharma
The FDA has approved Lipfendra, Merck’s oral PCSK9 inhibitor, to lower LDL cholesterol in patients on statins. Trials show ~55-60% LDL reductions; the pill will be sold at about $315/month and must be taken on an empty stomach. Analysts see potential peak sales in the billions as injectable rivals face competition and access barriers.
The FDA has approved daraxonrasib, sold as Rasonque by Revolution Medicines, for adults with previously treated or ineligible metastatic pancreatic cancer. Clinical trials have shown median survival extended to about 13.2 months versus roughly 6.7 months with chemotherapy. The drug will be available in the US with a roughly $39,800 monthly list price and expanded-access programmes have already treated thousands.